Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current portion of long-term debt $4,474,131 $2,651,592 Current portion of capital lease obligation - 41,641 Accounts payable 3,708,060 2,466,052 Accrued expenses 6,060,141 6,182,417 Deferred rent 124,462 124,463 Deferred revenue 1,857,136 1,857,136 --------- --------- Total current liabilities 16,223,930 13,323,301 DEFERRED RENT 48,421 79,793 DEFERRED REVENUE 3,404,674 3,868,965 LONG-TERM DEBT, net 18,053,545 16,522,665 ---------- ---------- Total liabilities 37,730,570 33,794,724 ---------- ---------- COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,390,862 and 23,340,498 shares issued and outstanding at December 31, 2008 (unaudited) and September 30, 2008, respectively 23,391 23,340 Warrants to purchase 127,248 and 116,183 shares of common stock for $12.05 per share, as of December 31, 2008, (unaudited) and September 30, 2008, respectively 1,229,767 1,140,114 Additional paid-in capital 147,600,186 145,818,439 Accumulated other comprehensive (loss) income (1,515) (2,604) Accumulated deficit (130,067,341) (111,791,944)
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today ... 2014. Biorem,s complete fiscal 2014 year-end financial statements and MD&A have been ... , 2013 , 2014 , 2013 Revenue ... 19,596 Gross profit 1,326 , 1,703 , 2,231 ... 1,493 , 3,377 , 4,562 Ebitda* 92 ...
(Date:4/29/2015)... 2015 Cambrex Corporation (NYSE: CBM ) announced ... Friday, May 1, 2015 before the market opens. , ... host a conference call to discuss the financial results. First ... , Friday, May 1, 2015 at 8:30 a.m. Eastern ... U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... The leading Regenerative Veterinary Medicine Company, VetStem ... cell therapy has processed more than 11,000 samples. ... successful treatment for horses with potentially fatal injuries to ... worldwide exclusive license for adipose-derived (fat derived) stem cell ... treated in January 2004. Shortly after, the first dogs ...
(Date:4/29/2015)... - Northern Biologics Inc., a privately held biotechnology company ... strategic collaboration with Celgene Corporation.  As part of ... upfront cash payment. It will use the funds ... will have the right to receive additional future ... Under the agreement, Northern Biologics ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... predicting and quashing environmental decoherence, a phenomenon that has proven ... the way of quantum computing. The findings based ... and confirmed by experiments at the University of California Santa ... of the journal Nature . Quantum mechanics states ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
... July 20, 2011 ReSearch Pharmaceutical Services, Inc. ... global Phase II-IV clinical development solutions to the ... following key additions to its Operational and Senior ... Davis, II, as Chief Information Officer and Executive ...
Cached Biology Technology:Discovery may overcome obstacle for quantum computing 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 2RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 3
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... 26, 2011Magnetic resonance tractography (MRT) is a valuable, ... and, as MRT methods and technologies advance, has ... on brain activity and connectivity. Critical information about ... explored in a forward-looking review article in the ...
... Texas at Austin researchers have discovered how to extract and ... objects are from the focus distance, a feat only accomplished ... Like a camera, the human eye has an auto-focusing system, ... humans do not require trial and error to focus an ...
... used local anesthetic, may more easily wiggle into a ... compounds that carry a negative charge, a new study ... more complete understanding of the molecular-level mechanisms behind pain-blocking ... use. Most scientists believe that local anesthetics prevent ...
Cached Biology News:Researchers develop optimal algorithm for determining focus error in eyes and cameras 2
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: